OssDsign Catalyst now available on the U.S. market
Uppsala, Sweden, 08:00 CET, 16 August 2021 – OssDsign today announces that OssDsign Catalyst has been launched and is now ready for sale in the U.S. This marks an important step in the company’s strategy of entering the highly scalable bone graft market with its innovative nanosynthetic bone graft that stimulates the formation of healthy bone tissue.
Nearly 80 percent of all Americans experience low back pain at some point in their lives and more than 1.5 million will undergo spinal fusion surgery. Approximately 20 percent of these surgeries are unsuccessful due to the lack of proper fusion between implants and the spine.
“We have now completed a major commercial milestone and delivered on our promise to launch OssDsign Catalyst in the U.S. during the second half of 2021. The fact that we already now have managed to scale up production and make the product available for the US market is a great achievement by the entire team at OssDsign. We are confident that OssDsign Catalyst will improve the clinical outcome for many patients”, comments Morten Henneveld, CEO, OssDsign.
OssDsign Catalyst is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. This innovative graft is composed of a proprietary nanocrystalline structure that can be implanted into the spine and is then resorbed and replaced by new bone tissue. Data from a recently published pre-clinical study show that OssDsign Catalyst induced rapid and reliable bone formation and that successful fusion was achieved in 100% of the studied subjects at 26 weeks, compared to 60% in the group where a comparable market-cleared device was used.
OssDsign Catalyst received FDA clearance in 2020 and the addressable market for synthetic bone grafts in spinal surgeries is valued at USD 2.6 billion with an expected CAGR of 7% during 2021–2025.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: email@example.com
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: firstname.lastname@example.org.
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.